FDA Upgraded Thyroid Tablet Recall to Class I
Wholesalers must destroy inventory of affected thyroid medication after the manufacturer ceased operations.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Do you trust pharmaceutical companies to ensure drug safety even after they cease operations?
The FDA has reclassified a recall of Vitruvias Therapeutics thyroid tablets to Class I, indicating a risk of serious health consequences. The action follows the company's decision to cease all business operations.
Why it matters
The reclassification stems from the potential for the pills to be superpotent, posing significant risks for vulnerable populations including pregnant women and the elderly. This shift intensifies compliance urgency for wholesalers holding the inventory.
Approximately 2,000 bottles from lot number 504950 were distributed nationwide between Jan. 31, 2025, and Sept. 30, 2025. H2-Pharma LLC now manages the distribution of the defunct manufacturer's former product portfolio.
The players
FDA
The federal agency responsible for protecting public health through the regulation of food, drugs, and medical devices.
Vitruvias Therapeutics
A pharmaceutical manufacturer that has now ceased all business operations.
H2-Pharma LLC
A distributor and owner of products formerly held by Vitruvias Therapeutics.
The details
The FDA elevated the alert to a Class I classification, the most serious level, after Vitruvias Therapeutics halted all business operations. Wholesalers have been directed to stop distribution immediately and move to destroy all remaining inventory associated with the affected lot. The tablets are marked with an expiration date of Sept. 30, 2026.
Timeline
Jan. 31, 2025: Distribution of the affected lot began.
Sept. 30, 2025: Distribution of the affected lot ended.
Sept. 23, 2026: The FDA reclassified the recall to Class I.
Sept. 30, 2026: The affected medication expires.
Market Landscape
This reclassification follows the established pattern of the FDA Class I recall classification criteria for products posing a high probability of serious adverse health consequences. The move highlights how the agency manages safety mandates when a manufacturer becomes defunct.
Wholesalers and pharmacies must immediately verify stock against lot number 504950 and ensure those units are pulled from shelves and destroyed. Operators should track the status of products formerly produced by defunct entities through active FDA enforcement databases.
The takeaway
The sudden closure of a manufacturer does not pause the obligation to manage active safety risks in the supply chain. Operators should maintain a list of active recalls and verify that inventory disposal protocols are documented to maintain compliance with FDA standards.
Further reading
For more on regulatory safety standards, see the latest updates in Healthcare.
Live Poll
Do you trust pharmaceutical companies to ensure drug safety even after they cease operations?
